299 related articles for article (PubMed ID: 27154187)
1. Minihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera.
Casu C; Oikonomidou PR; Chen H; Nandi V; Ginzburg Y; Prasad P; Fleming RE; Shah YM; Valore EV; Nemeth E; Ganz T; MacDonald B; Rivella S
Blood; 2016 Jul; 128(2):265-76. PubMed ID: 27154187
[TBL] [Abstract][Full Text] [Related]
2. Minihepcidins improve ineffective erythropoiesis and splenomegaly in a new mouse model of adult β-thalassemia major.
Casu C; Chessa R; Liu A; Gupta R; Drakesmith H; Fleming R; Ginzburg YZ; MacDonald B; Rivella S
Haematologica; 2020 Jul; 105(7):1835-1844. PubMed ID: 31582543
[TBL] [Abstract][Full Text] [Related]
3. An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia.
Schmidt PJ; Toudjarska I; Sendamarai AK; Racie T; Milstein S; Bettencourt BR; Hettinger J; Bumcrot D; Fleming MD
Blood; 2013 Feb; 121(7):1200-8. PubMed ID: 23223430
[TBL] [Abstract][Full Text] [Related]
4. Deletion of TMPRSS6 attenuates the phenotype in a mouse model of β-thalassemia.
Nai A; Pagani A; Mandelli G; Lidonnici MR; Silvestri L; Ferrari G; Camaschella C
Blood; 2012 May; 119(21):5021-9. PubMed ID: 22490684
[TBL] [Abstract][Full Text] [Related]
5. Global loss of Tfr2 with concomitant induced iron deficiency greatly ameliorates the phenotype of a murine thalassemia intermedia model.
Schmidt PJ; Fitzgerald K; Butler JS; Fleming MD
Am J Hematol; 2021 Feb; 96(2):251-257. PubMed ID: 33180328
[TBL] [Abstract][Full Text] [Related]
6. Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin.
Gardenghi S; Marongiu MF; Ramos P; Guy E; Breda L; Chadburn A; Liu Y; Amariglio N; Rechavi G; Rachmilewitz EA; Breuer W; Cabantchik ZI; Wrighting DM; Andrews NC; de Sousa M; Giardina PJ; Grady RW; Rivella S
Blood; 2007 Jun; 109(11):5027-35. PubMed ID: 17299088
[TBL] [Abstract][Full Text] [Related]
7. Erythroferrone exacerbates iron overload and ineffective extramedullary erythropoiesis in a mouse model of β-thalassemia.
Olivera J; Zhang V; Nemeth E; Ganz T
Blood Adv; 2023 Jul; 7(14):3339-3349. PubMed ID: 36995275
[TBL] [Abstract][Full Text] [Related]
8. Hepcidin agonists as therapeutic tools.
Casu C; Nemeth E; Rivella S
Blood; 2018 Apr; 131(16):1790-1794. PubMed ID: 29523504
[TBL] [Abstract][Full Text] [Related]
9. β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism.
Ginzburg Y; Rivella S
Blood; 2011 Oct; 118(16):4321-30. PubMed ID: 21768301
[TBL] [Abstract][Full Text] [Related]
10. SLN124, a GalNac-siRNA targeting transmembrane serine protease 6, in combination with deferiprone therapy reduces ineffective erythropoiesis and hepatic iron-overload in a mouse model of β-thalassaemia.
Vadolas J; Ng GZ; Kysenius K; Crouch PJ; Dames S; Eisermann M; Nualkaew T; Vilcassim S; Schaeper U; Grigoriadis G
Br J Haematol; 2021 Jul; 194(1):200-210. PubMed ID: 33942901
[TBL] [Abstract][Full Text] [Related]
11. Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of β-thalassemia.
Manolova V; Nyffenegger N; Flace A; Altermatt P; Varol A; Doucerain C; Sundstrom H; Dürrenberger F
J Clin Invest; 2019 Dec; 130(1):491-506. PubMed ID: 31638596
[TBL] [Abstract][Full Text] [Related]
12. mRNA expression of iron regulatory genes in beta-thalassemia intermedia and beta-thalassemia major mouse models.
Weizer-Stern O; Adamsky K; Amariglio N; Rachmilewitz E; Breda L; Rivella S; Rechavi G
Am J Hematol; 2006 Jul; 81(7):479-83. PubMed ID: 16755567
[TBL] [Abstract][Full Text] [Related]
13. Hepcidin is suppressed by erythropoiesis in hemoglobin E β-thalassemia and β-thalassemia trait.
Jones E; Pasricha SR; Allen A; Evans P; Fisher CA; Wray K; Premawardhena A; Bandara D; Perera A; Webster C; Sturges P; Olivieri NF; St Pierre T; Armitage AE; Porter JB; Weatherall DJ; Drakesmith H
Blood; 2015 Jan; 125(5):873-80. PubMed ID: 25519750
[TBL] [Abstract][Full Text] [Related]
14. Modulation of hepcidin as therapy for primary and secondary iron overload disorders: preclinical models and approaches.
Schmidt PJ; Fleming MD
Hematol Oncol Clin North Am; 2014 Apr; 28(2):387-401. PubMed ID: 24589273
[TBL] [Abstract][Full Text] [Related]
15. Liver expression of hepcidin and other iron genes in two mouse models of beta-thalassemia.
De Franceschi L; Daraio F; Filippini A; Carturan S; Muchitsch EM; Roetto A; Camaschella C
Haematologica; 2006 Oct; 91(10):1336-42. PubMed ID: 17018382
[TBL] [Abstract][Full Text] [Related]
16. Anemia, ineffective erythropoiesis, and hepcidin: interacting factors in abnormal iron metabolism leading to iron overload in β-thalassemia.
Gardenghi S; Grady RW; Rivella S
Hematol Oncol Clin North Am; 2010 Dec; 24(6):1089-107. PubMed ID: 21075282
[TBL] [Abstract][Full Text] [Related]
17. Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of β-thalassemia.
Kautz L; Jung G; Du X; Gabayan V; Chapman J; Nasoff M; Nemeth E; Ganz T
Blood; 2015 Oct; 126(17):2031-7. PubMed ID: 26276665
[TBL] [Abstract][Full Text] [Related]
18. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice.
Gardenghi S; Ramos P; Marongiu MF; Melchiori L; Breda L; Guy E; Muirhead K; Rao N; Roy CN; Andrews NC; Nemeth E; Follenzi A; An X; Mohandas N; Ginzburg Y; Rachmilewitz EA; Giardina PJ; Grady RW; Rivella S
J Clin Invest; 2010 Dec; 120(12):4466-77. PubMed ID: 21099112
[TBL] [Abstract][Full Text] [Related]
19. RNAi-mediated reduction of hepatic Tmprss6 diminishes anemia and secondary iron overload in a splenectomized mouse model of β-thalassemia intermedia.
Schmidt PJ; Liu K; Visner G; Fitzgerald K; Fishman S; Racie T; Hettinger JL; Butler JS; Fleming MD
Am J Hematol; 2018 Jun; 93(6):745-750. PubMed ID: 29498084
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of β-thalassemia intermedia.
Schmidt PJ; Racie T; Westerman M; Fitzgerald K; Butler JS; Fleming MD
Am J Hematol; 2015 Apr; 90(4):310-3. PubMed ID: 25557851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
